Differential effects of stimulants on monoaminergic transporters: Pharmacological consequences and implications for neurotoxicity

European Journal of Pharmacology

Volumn 406, Issue 1, 2000, Pages 1-13

  Fleckenstein, Annette E ^a   Gibb, James W ^a   Hanson, Glen R ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Amphetamine; Dopamine trasporter; Psychostimulant

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; COCAINE; DOPAMINE TRANSPORTER; FENFLURAMINE; METHCATHINONE; METHYLPHENIDATE;

CELL MEMBRANE; DOPAMINE RELEASE; DOPAMINE UPTAKE; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; IC 50; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; REVIEW;

ANIMALS; CARRIER PROTEINS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; METHAMPHETAMINE; NERVE TISSUE PROTEINS; NERVOUS SYSTEM; NEUROPEPTIDES; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SYMPORTERS; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 0034613214     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00639-7     Document Type: Review

References (103)

1. Albers D.S., Sonsalla P.K. Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: Pharmacological profile of protective and nonprotective agents. J. Pharmacol. Exp. Ther. 275:1995;1104-1114.
2. Appel N.M., Mitchell W.M., Contrera J.F., De Souza E.B. Effects of high-dose fenfluramine treatment on monoamine uptake sites in rat brain: assessment using quantitative autoradiography. Synapse. 6:1990;33-44.
3. Axt K.J., Molliver M.E. Immunocytochemical evidence for methamphetamine-induced serotonergic axon loss in the rat brain. Synapse. 9:1991;302-313.
4. 3H]paroxetine-labeled serotonin uptake sites. J. Pharmacol. Exp. Ther. 242:1987;911-916.
5. Benmansour S., Tejani-Butt S.M., Hauptmann M., Brunswick D.J. Lack of effect of high-dose cocaine on monoamine uptake sites in rat brain measured by quantitative autoradiography. Psychopharmacology (Berlin). 106:1992;459-462.
6. Berman S.B., Zigmond M.J., Hastings T.G. Modification of dopamine transporter function: effect of reactive oxygen species and dopamine. J. Neurochem. 67:1996;593-600.
7. Blakely R.D., Ramamoorthy S., Schroeter S., Qian Y., Apparsundaram S., Galli A., DeFelice L.J. Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins. Biol. Psychiatry. 44:1998;169-178.
8. Bowyer J.F., Davies D.L., Schmued L., Broening H.W, Newport G.D., Slikker W., Holson R.R. Further studies of hyperthermia in methamphetamine neurotoxicity. J. Pharmacol. Exp. Ther. 268:1994;1571-1580.
9. Brown J.M., Hanson G.R., Fleckenstein A.E. Methamphetamine rapidly decreases vesicular dopamine uptake. J. Neurochem. 74:2000;2221-2223.
10. Brown J.M., Hanson G.R., Fleckenstein A.E. The vesicular monoamine transporter-2: a novel site of cocaine action. Soc. Neurosci. Abstr. 2000;. #11413.
11. Buening M.K., Gibb J.W. Influence of methamphetamine and neuroleptic drugs on tyrosine hydroxylase activity. Eur. J. Pharmacol. 26:1974;30-34.
12. Cadet J.L., Sheng P., Ali S., Rothman R., Carlson E., Epstein C. Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. J. Neurochem. 62:1994;380-383.
13. Cappon G.D., Broening H.W., Pu C., Morford L., Vorhees C.V. alpha-Phenyl-N-tert-butyl nitrone attenuates methamphetamine-induced depletion of striatal dopamine without altering hyperthermia. Synapse. 24:1996;173-181.
14. Cappon G.D., Morford L.L., Vorhees C.V. Enhancement of cocaine-induced hyperthermia fails to elicit neurotoxicity. Neurotoxicol. Teratol. 20:1998;531-535.
15. Copeland B.J., Vogelsberg V., Neff N.H., Hadjiconstantinou M. Protein kinase C activators decrease dopamine uptake into striatal synaptosomes. J. Pharmacol. Exp. Ther. 277:1996;1527-1532.
16. Cowell R.M., Kantor L., Hewlett G.H., Frey K.A., Gnegy M.E. Dopamine transporter antagonists block phorbol ester-induced dopamine release and dopamine transporter phosphorylation in striatal synaptosomes. Eur. J. Pharmacol. 389:2000;59-65.
17. Cubells J.F., Rayport S., Rajendran G., Sulzer D. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 14:1994;2260-2271.
18. DeVito M.J., Wagner G.C. Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacology. 28:1989;1145-1150.
19. Eisch A.J., Gaffney M., Weihmuller F.B., O'Dell S.J., Marshall J.F. Striatal subregions are differentially vulnerable to the neurotoxic effects of methamphetamine. Brain Res. 598:1992;321-326.
20. Farfel G.M., Seiden L.S. Role of hypothermia in the mechanism of protection against serotonergic toxicity: II. Experiments with methamphetamine, p-chloroamphetamine, fenfluramine, dizocilpine and dextromethorphan. J. Pharmacol. Exp. Ther. 272:1995;868-875.
21. Fleckenstein A.E., Haughey H.M., Metzger R.R., Kokoshka J.M., Riddle E.L., Hanson J.E., Gibb J.W., Hanson G.R. Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function. Eur. J. Pharmacol. 382:1999;45-49.
22. Fleckenstein A.E., Metzger R.R., Beyeler M.B., Gibb J.W., Hanson G.R. Oxygen radicals diminish dopamine transporter function in rat striatum. Eur. J. Pharmacol. 334:1997;111-114.
23. Fleckenstein A.E., Metzger R.R., Wilkins D.G., Gibb J.W., Hanson G.R. Rapid and reversible effects of methamphetamine on dopamine transporters. J. Pharmacol. Exp. Ther. 282:1997;834-838.
24. Fleckenstein A.E., Wilkins D.G., Gibb J.W., Hanson G.R. Interaction between free radical formation and hyperthermia in the serotonergic response to a single methamphetamine administration. J. Pharmacol. Exp. Ther. 283:1997;281-285.
25. Fumagalli F., Gainetdinov R.R., Wang Y.M., Valenzano K.J., Miller G.W., Caron M.G. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J. Neurosci. 19:1999;2424-2431.
26. Giambalvo C.T. Protein kinase C and dopamine transport - 1. Effects of amphetamine in vivo. Neuropharmacology. 31:1992;1201-1210.
27. Gibb J.W., Kogan F.J. Influence of dopamine synthesis on methamphetamine-induced changes in striatal and adrenal tyrosine hydroxylase activity. Naunyn-Schmiedeberg's Arch. Pharmacol. 310:1979;185-187.
28. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14:1978;633-643.
29. Gudelsky G.A. Effect of ascorbate and cysteine on the 3,4-methylenedioxymethamphetamine-induced depletion of brain serotonin. J. Neural Transm. 103:1996;1397-1404.
30. Gygi M.P., Gibb J.W., Hanson G.R. Methcathinone: an initial study of its effects on monoaminergic systems. J. Pharmacol. Exp. Ther. 276:1996;1066-1072.
31. Gygi M.P., Fleckenstein A.E., Gibb J.W., Hanson G.R. Role of endogenous dopamine in the neurochemical deficits induced by methcathinone. J. Pharmacol. Exp. Ther. 283:1997;1350-1355.
32. --dependent transporters. Eur. J. Pharmacol. 379:1999;107-110.
33. --dependent transporters. Brain Res. 863:2000;59-63.
34. Haughey, H.M., Fleckenstein, A.E., Metzger, R.R., Hanson, G.R., in press. Effects of methamphetamine on serotonin transporter activity: Role of dopamine and hyperthermia. J. Neurochem.
35. 3H]dopamine in rat brain tissue slices. Biochem. Pharmacol. 24:1975;847-852.
36. Hirata H., Ladenheim B., Rothman R.B., Epstein C., Cadet J.L. Methamphetamine-induced serotonin neurotoxicity is mediated by superoxide radicals. Brain Res. 677:1995;345-347.
37. 3H]-DHTB binding to VMAT2, is compromised 24 h after methamphetamine treatment. Soc. Neurosci. Abstr. 25:1999;1965.
38. Hogan K.A., Staal R.G., Sonsalla P.K. Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations. J. Neurochem. 74:2000;2217-2220.
39. Holson R.R., Bowyer J.F., Clausing P., Gough B. Methamphetamine-stimulated striatal dopamine release declines rapidly over time following microdialysis probe insertion. Brain Res. 739:1996;301-307.
40. Hotchkiss A.J., Gibb J.W. Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase in rat brain. J. Pharmacol. Exp. Ther. 214:1980;257-262.
41. Hotchkiss A.J., Morgan M.E., Gibb J.W. The long-term effects of multiple doses of methamphetamine on neostriatal tryptophan hydroxylase, tryosine hydroxylase, choline acetyltransferase and glutamate decarboxylase activities. Life Sci. 25:1979;1373-1378.
42. Huang C.L., Chen H.C., Huang N.K., Yang D.M., Kao L.S., Chen J.C., Lai H.L., Chern Y. Modulation of dopamine transporter activity by nicotinic acetylcholine receptors and membrane depolarization in rat pheochromocytoma PC12 cells. J. Neurochem. 72:1999;2437-2444.
43. Huff R.A., Vaughan R.A., Kuhar M.J., Uhl G.R. Enhancement of dopamine transporter phosphorylation by phorbol esters: parallels with phorbol-induced decreases in transport. Soc. Neurosci. 1996;. 207.11.
44. Insel T.R., Battaglia G., Johannessen J.N., Marra S., De Souza E.B. 3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys. J. Pharmacol. Exp. Ther. 249:1989;713-720.
45. Jackson R.T., Hersey S.J. Interaction of cocaine with nasal mucosa. Arch. Otolaryngol., Head Neck Surg. 117:1991;975-979.
46. Johnson M., Letter A.A., Merchant K., Hanson G.R., Gibb J.W. Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat. J. Pharmacol. Exp. Ther. 244:1988;977-982.
47. Jones S.R., Joesph J.D., Barak L.S., Caron M.G., Wightman R.M. Dopamine neuronal transport kinetics and effects of amphetamine. J. Neurochem. 73:1999;2406-2414.
48. Kantor L., Gnegy M.E. Protein kinase C inhibitors block amphetamine-mediated dopamine release in rat striatal slices. J. Pharmacol. Exp. Ther. 284:1998;592-598.
49. Kim S., Westphalen R., Callahan B., Hatzidimitriou G., Yuan J., Ricaurte G.A. Toward development of an in vitro model of methamphetamine-induced dopamine nerve terminal toxicity. J. Pharmacol. Exp. Ther. 293:2000;625-633.
50. Kitayama S., Dohi T., Uhl G.R. Phorbol esters alter functions of the expressed dopamine transporter. Eur. J. Pharmacol. 268:1994;115-119.
51. Kleven M.S., Woolverton W.L., Seiden L.S. Lack of long-term monoamine depletions following repeated or continuous exposure to cocaine. Brain Res. Bull. 21:1988;233-237.
52. Kokoshka J.M., Metzger R.R., Wilkins D.G., Gibb J.W., Hanson G.R., Fleckenstein A.E. Methamphetamine treatment rapidly inhibits serotonin, but not glutamate, transporters in rat brain. Brain Res. 799:1998;78-83.
53. Kokoshka J.M., Vaughan R.A., Hanson G.R., Fleckenstein A.E. Nature of methamphetamine-induced rapid and reversible changes in dopamine transporters. Eur. J. Pharmacol. 361:1998;269-275.
54. 3H]cyanoimipramine autoradiography. Brain Res. 505:1989;123-129.
55. LaVoie M.J., Hastings T.G. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J. Neurosci. 19:1999;1484-1491.
56. 3H]dopamine from isolated corpus striatum by amphetamine, fenfluramine and unlabelled dopamine. Biochem. Pharmacol. 31:1982;983-992.
57. + toxicity encodes a vesicular amine transporter. Cell. 70:1992;539-551.
58. Marek G.J., Vosmer G., Seiden L.S. Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine upon dopaminergic neurons. Brain Res. 513:1990;274-279.
59. 11C]WIN-35,428. J. Neurosci. 18:1998;8417-8422.
60. McCann U.D., Yuan J., Hatzidimitriou G., Ricaurte G.A. Selective serotonin reuptake inhibitors dissociate fenfluramine's anorectic and neurotoxic effects: importance of dose, species and drug. J. Pharmacol. Exp. Ther. 281:1997;1487-1498.
61. Melikian H.E., Buckley K.M. Membrane trafficking regulates the activity of the human dopamine transporter. J. Neurosci. 19:1999;7699-7710.
62. Metzger R.R., Hanson G.R., Gibb J.W., Fleckenstein A.E. Methylenedioxymethamphetamine-induced acute changes in dopamine transporter function. Eur. J. Pharmacol. 349:1998;205-210.
63. Metzger, R.R., Haughey, H.M., Wilkins, D.G., Gibb, J.W., Hanson, G.R., Fleckenstein, A.E. Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia; J. Pharmacol. Exp Ther., in press.
64. Miller G.W., Gainetdinov R.R., Levey A.I., Caron M.G. Dopamine transporters and neuronal injury. TIPS. 20:1999;424-429.
65. Morgan M.E., Gibb J.W. Short-term and long-term effects of methamphetamine on biogenic amine metabolism in extra-striatal dopaminergic nuclei. Neuropharmacology. 10:1980;989-995.
66. Nash J.F., Yamamoto B.K. Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res. 581:1992;237-243.
67. Nicolaysen L.C., Justice J.B. Effects of cocaine on release and dopamine uptake of dopamine in vivo: differentiation by mathematical modeling. Pharmacol. Biochem. Behav. 31:1988;327-335.
68. O'Dell S.J., Weihmuller F.B., Marshall J.F. Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity. Brain Res. 564:1991;256-260.
69. Pacholczyk T., Blakely R.D., Amara S.G. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature. 350:1991;350-354.
70. Peat M.A., Warren P.F., Bakhit C., Gibb J.W. The acute effects of methamphetamine, amphetamine, and p-chloroamphetamine on the cortical serotonergic system of the rat brain: evidence for differences in the effects of methamphetamine and amphetamine. Eur. J. Pharmacol. 116:1985;11-16.
71. 3H]dopamine uptake. Brain Res. 643:1994;83-91.
72. Preston K.L., Wagner G.C., Schuster C.R., Seiden L.S. Long-term effects of repeated methylamphetamine administration on monoamine neurons in the rhesus monkey brain. Brain Res. 338:1985;243-248.
73. Pristupa Z.B., McConkey F., Liu F., Man H.Y., Lee F.J., Wang Y.T., Niznik H.B. Protein kinase-mediated bi-directional trafficking and functional regulation of the human dopamine transporter. Synapse. 30:1998;79-87.
74. Ramamoorthy S., Blakely R.D. Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science. 285:1999;763-766.
75. Ricaurte G.A., Fuller R.W., Perry K.W., Seiden L.S., Schuster C.R. Fluoxetine increases long-lasting neostriatal dopamine depletion after administration of D-methamphetamine and D-amphetamine. Neuropharmacology. 22:1983;1165-1169.
76. Ricaurte G.A., Guillery R.W., Seiden L.S., Schuster C.R., Moore R.Y. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res. 235:1982;93-103.
77. Ricaurte G.A., Seiden L.S., Schuster C.R. Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve terminals. Brain Res. 303:1984;359-364.
78. Ricaurte G., Bryan G., Strauss L., Seiden L., Schuster C. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science. 229:1985;986-988.
79. Sandoval V., Kokoshka J.M., Hanson G.R., Fleckenstein A.E. Methamphetamine rapidly and reversibly decreases dopamine transporter activity in mouse striatum. Soc. Neurosci., Abstr. 1999;. 23.16.
80. Sandoval V., Ugarte Y.V., Gibb J.W., Hanson G.R., Fleckenstein A.E. An in vitro model of the rapid and reversible decrease in dopamine transporter function caused by methamphetamine administration: a phenomenon distinct from neurotoxicity. Soc. Neurosci. Abstr. 2000;. submitted.
81. Saunders C., Ferrer J.V., Shi L., Chen J., Merrill G., Lamb M.E., Leeb-Lundberg L.M., Carvelli L., Javitch J.A., Galli A. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc. Natl. Acad. Sci. 97:2000;6850-6855.
82. 123/125I]RTI-55, an in vivo label for the serotonin transporter. Synapse. 11:1992;134-139.
83. Schmidt C.J., Ritter J.K., Sonsalla P.K., Hanson G.R., Gibb J.W. Role of dopamine in the neurotoxic effects of methamphetamine. J. Pharmacol. Exp. Ther. 233:1985;539-544.
84. Seiden L.S., Fischman M.W., Schuster C.R. Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend. 1:1976;215-219.
85. Sonsalla P.K., Gibb J.W., Hanson G.R. Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems. J. Pharmacol. Exp. Ther. 238:1986;932-937.
86. Speciale S.G., Liang C.L., Sonsalla P.K., Edwards R.H., German D.C. The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter. Neuroscience. 84:1998;1177-1185.
87. Staal R.G., Sonsalla P.K. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. J. Pharmacol. Exp. Ther. 293:2000;336-342.
88. Stone D.M., Stahl D.C., Hanson G.R., Gibb J.W. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J. Pharmacol. 128:1986;41-48.
89. Stone D.M., Johnson M., Hanson G.R., Gibb J.W. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 24:1988;79-87.
90. Suzuki O., Hattori H., Asano M., Oya M., Katsumata Y. Inhibition of monoamine oxidase by D-methamphetamine. Biochem. Pharmacol. 29:1980;2071-2073.
91. Vaughan R.A., Huff R.A., Uhl G.R., Kuhar M.J. Protein kinase C-mediated phosphorylation and functional regulation in striatal synaptosomes. Biol. Chem. 272:1997;15541-15546.
92. Wagner G.C., Lucot J.B., Schuster C.R., Seiden L.S. Alpha-methyltyrosine attenuates and reserpine increases methamphetamine-induced neuronal changes. Brain Res. 270:1983;258-285.
93. Wagner G.C., Ricaurte G.A., Seiden L.S., Schuster C.R., Miller R.J., Westley J. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 181:1980;151-160.
94. Wang J.B., Moriwaki A., Uhl G.R. Dopamine transporter cysteine mutants: second extracellular loop cysteines are required for transporter expression. J. Neurochem. 64:1995;1416-1419.
95. Wilson J.M., Kalasinsky K.S., Levey A.I., Bergeron C., Reiber G., Anthony R.M., Schmunk G.A., Shannak K., Haycock J.W., Kish S.J. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 2:1996;699-703.
96. Woolverton W.L., Ricaurte G.A., Forno L., Seiden L.S. Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res. 486:1989;73-78.
97. Yamamoto B.K., Zhu W. The effects of methamphetamine on the production of free radicals and oxidative stress. J. Pharmacol. Exp. Ther. 287:1998;107-114.
98. Yeh S.Y., De Souza E.B. Lack of neurochemical evidence for neurotoxic effects of repeated cocaine administration in rats on brain monoamine neurons. Drug Alcohol Depend. 27:1991;51-61.
99. Yuan J., McCann U., Ricaurte G. Methylphenidate and brain dopamine neurotoxicity. Brain Res. 767:1997;172-175.
100. Zaczek R., Battaglia G., Contrera J.F., Culp S., De Souza E.B. Methylphenidate and pemoline do not cause depletion of rat brain monoamine markers similar to that observed with methamphetamine. Toxicol. Appl. Pharmacol. 100:1989;227-233.
101. Zaczek R., Battaglia G., Culp S., Appel N.M., Contrera J.F., De Souza E.B. Effects of repeated fenfluramine administration on indices of monoamine function in rat brain: pharmacokinetic, dose response, regional specificity and time course data. J. Pharmacol. Exp. Ther. 253:1990;104-112.
102. Zhang L., Reith M.E. Regulation of the functional activity of the human dopamine transporter by the arachidonic acid pathway. Eur. J. Pharmacol. 315:1996;345-354.
103. Zhang L., Coffey L.L., Reith M.E. Regulation of the functional activity of the human dopamine transporter by protein kinase C. Biochem. Pharmacol. 53:1997;677-688.